Analysis of Autoantibodies against Promyelocytic Leukemia Nuclear Body Components and Biochemical Parameters in Sera of Patients with Primary Biliary Cholangitis

Bauer, Alicja; Habior, Andrzej; Wieszczy, Paulina; Gawel, Damian

doi:10.3390/diagnostics11040587

Cited by 6 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We confirmed that the prevalence of anti‐Sp100 antibodies in PBC patients was within the previously reported ranges, 6‐15 but no significant difference in the frequency of anti‐Sp100 was not detected between the AMA‐positive and AMA‐negative PBC patients, indicating that anti‐Sp100 cannot become a complementary serological marker of PBC in AMA‐negative patients. Our analyses also did not elucidate that anti‐Sp100 was associated with the disease severity, which did not support the previous studies 5,11,18 …”

Section: Discussionsupporting

confidence: 89%

“…The reported prevalence of anti‐Sp100 in PBC patients ranged from 8.7% to 40.0% in PBC patients, 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 and it has been speculated that the detection of these antibodies might be useful for the diagnosis of PBC, especially in the patients who were seronegative for AMAs. 16 , 17 Faster disease progression was observed in PBC patients with anti‐Sp100 compared to PBC patients without anti‐Sp100.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical impact of antibodies to Sp100 on a bacterial infection in patients with primary biliary cholangitis

Himoto

Yamamoto

Morimoto

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background A specific antinuclear antibody for primary biliary cholangitis (PBC) is anti‐Sp100, which was recognized as a serological marker of concurrent urinary tract infection. We sought to determine the clinical characteristics of PBC patients who had anti‐Sp100. Patients and Methods Fifty‐one patients with PBC and 10 healthy controls (HCs) were enrolled. Anti‐Sp100 were determined with an ELISA method. Lipopolysaccharide‐binding protein (LBP) was measured as a serological hallmark for bacterial infection. The correlations of anti‐Sp100 with demographic, laboratory, and pathological parameters were investigated. Results Six of the 51 (11.8%) PBC patients had anti‐Sp100, whereas none of the HCs did. There was no significant difference in the frequency of antimitochondrial antibodies (AMAs) between PBC patients with and without anti‐Sp100 (67% vs. 82%, p = 0.5839). Biochemical and immunological parameters were not associated with the emergence of anti‐Sp100 in these patients. The clinical stage by Scheuer classification was not correlated with the existence of anti‐Sp100. No significant difference in the serum LBP levels was found between PBC patients with and without anti‐Sp‐100, although serum LBP levels were significantly higher in PBC patients with anti‐Sp100 than in HCs (8.30 ± 2.24 ng/ml, vs. 5.12 ± 2.48 ng/ml, p = 0.0022). The frequency of granuloma formation was higher in the liver specimens of PBC patients with anti‐Sp100 than in those without anti‐Sp100 (67% vs 29%, p = 0.0710). Conclusion anti‐Sp100 does not become a complementary serological marker for PBC in AMA‐negative patients. A bacterial infection may trigger the production of anti‐Sp100. Another factor is required to initiate the autoantibody production.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Clinical impact of antibodies to Sp100 on a bacterial infection in patients with primary biliary cholangitis

Himoto

Yamamoto

Morimoto

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…From a prognostication standpoint, a decline of anti-Sp100 titers has been shown to be correlated with improvement in Mayo clinical risk score and response to ursodeoxycholic acid therapy (Mytilinaiou et al, 2012;Gatselis et al, 2013). Similarly, it has also been reported that anti-Sp100 or anti-PML titer is associated with more advanced liver histological staging and higher serum biochemistry (Bauer et al, 2021). As it stands, anti-Sp100 may be helpful for the diagnosis of PBC, however its utility for prognostication or defining a unique clinical phenotype remains unclear.…”

Section: Anti-centromere Abmentioning

confidence: 99%

A Review on Biomarkers for the Evaluation of Autoimmune Cholestatic Liver Diseases and Their Overlap Syndromes

Nguyen

Fritzler²,

Swain³

2022

Front. Mol. Med

View full text Add to dashboard Cite

Autoimmune cholestatic liver disease includes both Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC). Both conditions result in impairment of hepatic bile flow ultimately leading to chronic liver injury, liver fibrosis and eventually end stage cirrhosis. Early and accurate diagnosis are important for the risk stratification, follow up and management of these patients. The underlying pathogenesis of these conditions have not been completely resolved and poses a barrier for the development of new diagnostic and prognostics tools. Current research work suggests that the pathogenesis of autoimmune cholestatic liver disease results from environmental, genetic, and a large component of underlying immune dysfunction. While the current available serum biomarkers and imaging modalities showcases progression in precision medicine for the management of autoimmune cholestatic liver disease, development of new biomarkers are still an area of need in this field. In this review, we will discuss the current and emerging biomarkers in patients with PBC, PSC, and a special population that exhibit overlap syndrome with autoimmune hepatitis (AIH). The use of these biomarkers for diagnosis and prognosis of these patients will be reviewed through the lens of the current understanding of the complex immune pathophysiology of these conditions.

show abstract

“…More than 90% of patients have circulating antimitochondrial autoantibodies (AMAs) [7,8], and about 30% to 50% of patients with PBC also have antinuclear antibodies, including anti-gp210, anti-p62 and anti-sp100. These anti-nuclear autoantibodies are associated with severe disease and poor outcomes [1,2,[9][10][11][12][13][14][15]. The inflammatory and destructive process leads to advanced fibrosis, cirrhosis, and liver failure.…”

Section: Introductionmentioning

confidence: 99%

Circulating Monocyte Chemoattractant Protein-1 (MCP-1) in Patients with Primary Biliary Cholangitis

Bauer,

Rawa

2024

IJMS

Self Cite

View full text Add to dashboard Cite

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that leads to the destruction of the intrahepatic bile ducts. While the inflammatory process can be mediated by monocyte chemotactic protein-1 (MCP-1), the importance of circulating MCP-1 as a biomarker is unclear. Our aim was to assess the diagnostic significance of the serum concentrations of MCP-1 in PBC patients. We compared circulating MCP-1 with biochemical, immunological and histological parameters. Serum samples were collected from 120 PBC patients, 60 pathologic controls and 30 healthy donors. MCP-1 levels were determined by using commercial enzyme-linked immunosorbent assay (ELISA). Elevated serum MCP-1 levels were detected in 66% of PBC patients with a specificity of 97%. Significantly higher levels of MCP-1 protein were found in the sera of patients with PBC than in the group of healthy individuals—410.2 pg/mL vs. 176.0 pg/mL, p < 0.01). Patients with higher concentrations of alkaline phosphatase also had higher levels of MCP-1 (r = 0.4, p < 0.01). In accordance with Ludwig’s classification, a positive correlation of serum MCP-1 concentration with the degree of fibrosis was observed, OR = 6.1, p = 0.0003. We compared the MCP-1 with procollagen type III, hyaluronic acid (HA), FIB-4 index, APRI and collagen type IV when predicting the advance of liver fibrosis. Circulating MCP-1 is better correlated with liver fibrosis and is also associated with the occurrence of specific antimitochondrial autoantibodies and specific anti-nuclear autoantibodies—anti-gp210. MPC-1 can be considered to be a tool for diagnosing the degree of fibrosis in PBC, and combinations of MCP-1 and other specific biomarkers could support the diagnosis of PBC.

show abstract

Analysis of Autoantibodies against Promyelocytic Leukemia Nuclear Body Components and Biochemical Parameters in Sera of Patients with Primary Biliary Cholangitis

Cited by 6 publications

References 36 publications

Clinical impact of antibodies to Sp100 on a bacterial infection in patients with primary biliary cholangitis

Clinical impact of antibodies to Sp100 on a bacterial infection in patients with primary biliary cholangitis

A Review on Biomarkers for the Evaluation of Autoimmune Cholestatic Liver Diseases and Their Overlap Syndromes

Circulating Monocyte Chemoattractant Protein-1 (MCP-1) in Patients with Primary Biliary Cholangitis

Contact Info

Product

Resources

About